Lynk Pharmaceuticals Receives NMPA Approval for Phase II Trial of LNK01004 Ointment

Why It Matters

The approval opens a fast‑track path to address two high‑unmet‑need skin disorders, potentially capturing a large market share and validating Lynk’s skin‑targeted JAK strategy.

Key Takeaways

• LNK01004 ointment cleared NMPA for Phase II vitiligo trial
• Phase II also approved for chronic hand eczema in China
• Pan-JAK inhibitor designed for skin‑restricted exposure, minimal systemic risk
• Preclinical data shows strong tissue selectivity and rapid clearance
• Lynk leverages AI‑driven design and protein degradation platform

Pulse Analysis

Lynk Pharmaceuticals announced that China’s National Medical Products Administration has granted permission to launch Phase II trials of its proprietary LNK01004 ointment for vitiligo and chronic hand eczema (CHE). Both conditions affect millions worldwide and lack curative options, especially in the Chinese market where prevalence is rising. By securing regulatory clearance for two distinct indications simultaneously, Lynk not only accelerates its clinical timeline but also positions itself to capture a sizable share of the dermatology segment, where topical therapies dominate treatment algorithms.

LNK01004 is a third‑generation soft pan‑JAK inhibitor engineered for skin‑restricted delivery. Unlike oral JAK blockers that expose patients to systemic immunosuppression, the ointment’s molecular design limits plasma concentration while achieving broad inhibition of cytokine pathways implicated in auto‑immune skin inflammation. Preclinical studies demonstrated rapid metabolism and a short plasma half‑life, translating into minimal systemic exposure and a favorable safety profile. Early data from an atopic dermatitis Phase II trial already showed meaningful repigmentation and itch reduction, suggesting the same efficacy‑safety balance could extend to vitiligo and CHE.

Beyond this single candidate, Lynk’s broader platform blends AI‑assisted molecular design with targeted protein degradation, enabling rapid iteration of small‑molecule therapeutics that aim to replace injectable biologics. The company’s leadership, drawn from Pfizer, MSD and Johnson & Johnson, lends credibility and may attract strategic partnerships or licensing deals, especially as global investors seek alternatives to high‑cost biologics. If Phase II results confirm efficacy, LNK01004 could become a first‑in‑class topical therapy, opening revenue streams in both China and export markets while reinforcing Lynk’s position as an emerging innovator in immune‑mediated dermatology.